Assessing the Impact of COVID-19 on HMPV Incidence and Severity Among Adults
1 other identifier
observational
2,197
1 country
1
Brief Summary
Human metapneumovirus (HMPV) is primarily recognized as a childhood pathogen, but its impact on adults remains largely underestimated. This study investigates the prevalence, clinical characteristics, and post-COVID-19 trends of HMPV infection among adults in Istanbul, Turkey.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Dec 2023
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
December 15, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 30, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
January 30, 2024
CompletedFirst Submitted
Initial submission to the registry
March 12, 2024
CompletedFirst Posted
Study publicly available on registry
March 13, 2024
CompletedMarch 13, 2024
March 1, 2024
15 days
March 12, 2024
March 12, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Prevalence of HMPV infection in adults pre- and post-COVID-19 pandemic
Analyse of data from adults with respiratory tract infections who were tested for various respiratory viruses using a multiplex PCR assay
Between 2016-2020 (pre-COVID) and 2021-2023 (post-COVID)
Secondary Outcomes (1)
Comparison of HMPV with other respiratory viruses in adults
Between 2016-2020 (pre-COVID) and 2021-2023 (post-COVID)
Study Arms (2)
Pre-COVID period
January 2016 to January 2020
Post-COVID period
January 2021 to September 2023
Interventions
Analyse of data from adults with respiratory tract infections who were tested for various respiratory viruses using a multiplex PCR assay
Eligibility Criteria
This retrospective study examined adults with acute respiratory tract infections in Istanbul, Turkey. Patients admitted between 2016-2020 (pre-COVID) and 2021-2023 (post-COVID) underwent multiplex PCR testing for various respiratory viruses, with a focus on human metapneumovirus. The study aimed to assess the prevalence of HMPV infection in adults and its potential change after the COVID-19 pandemic.
You may qualify if:
- Adults \>18 years
- Patients with acute respiratory tract infection symptoms
- Patients who underwent multiplex PCR testing for respiratory viruses
You may not qualify if:
- Patients for whom no respiratory viral panel test was conducted
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Acibadem University
Istanbul, Turkey (Türkiye)
Related Publications (5)
Niederman MS, Torres A. Respiratory infections. Eur Respir Rev. 2022 Oct 19;31(166):220150. doi: 10.1183/16000617.0150-2022. Print 2022 Dec 31.
PMID: 36261160BACKGROUNDHaas LE, Thijsen SF, van Elden L, Heemstra KA. Human metapneumovirus in adults. Viruses. 2013 Jan 8;5(1):87-110. doi: 10.3390/v5010087.
PMID: 23299785BACKGROUNDBoivin G, De Serres G, Hamelin ME, Cote S, Argouin M, Tremblay G, Maranda-Aubut R, Sauvageau C, Ouakki M, Boulianne N, Couture C. An outbreak of severe respiratory tract infection due to human metapneumovirus in a long-term care facility. Clin Infect Dis. 2007 May 1;44(9):1152-8. doi: 10.1086/513204. Epub 2007 Mar 28.
PMID: 17407031BACKGROUNDChow EJ, Uyeki TM, Chu HY. The effects of the COVID-19 pandemic on community respiratory virus activity. Nat Rev Microbiol. 2023 Mar;21(3):195-210. doi: 10.1038/s41579-022-00807-9. Epub 2022 Oct 17.
PMID: 36253478BACKGROUNDPearson V. Case studies. Baton Rouge puts community first. Trustee. 1995 May;48(5):24-6. No abstract available.
PMID: 10142898BACKGROUND
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
March 12, 2024
First Posted
March 13, 2024
Study Start
December 15, 2023
Primary Completion
December 30, 2023
Study Completion
January 30, 2024
Last Updated
March 13, 2024
Record last verified: 2024-03